



WHAT IS CLAIMED IS:

1. A compound selected from:



2. The compound of claim 1 selected from:




3. The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 15 which is:

((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)[8-(methoxymethyl)-6-(trifluoromethyl)imidazo[1,2-*a*]pyridin-2-yl]methanone,


- (6-bromo-8-((*S*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone,
 (6-bromo-8-((*R*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone,
 5 (6-bromo-7-methylimidazo[1,2-*a*]pyrimidin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone, or
 (6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone.

- 10 4. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.


15

6. The compound of claim 1, which is:



, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, which is:



20

, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, which is: ((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)[8-(methoxymethyl)-6-(trifluoromethyl)imidazo[1,2-*a*]pyridin-2-yl]methanone, or a pharmaceutically acceptable salt thereof.
- 5 9. The compound of claim 1, which is: (6-bromo-8-((*S*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone, or a pharmaceutically acceptable salt thereof.
- 10 10. The compound of claim 1, which is: (6-bromo-8-((*R*)-1-methoxyethyl)imidazo[1,2-*a*]pyridin-2-yl)((3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl)methanone, or a pharmaceutically acceptable salt thereof.
- 15 11. The compound of claim 1, which is: (6-bromo-7-methylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone, or a pharmaceutically acceptable salt thereof.
- 20 12. The compound of claim 1, which is: (6-cyclopropylimidazo[1,2-*a*]pyrimidin-2-yl)[(3*R*,3'*R*)-3'-hydroxy-1,4-dihydro-1'*H*,2*H*-spiro[isoquinoline-3,4'-piperidin]-1'-yl]methanone, or a pharmaceutically acceptable salt thereof.
- 25 13. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, for treating cancer.
15. The method for treating cancer comprising administering to a patient in need
30 thereof a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof.

16. The method for treating sickle cell disease comprising administering to a patient in need thereof a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof.
- 5 17. The method for treating hereditary persistence of foetal hemoglobin (HPFH) mutations comprising administering to a patient in need thereof a compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof.
18. The use of a compound of any of claims 1-12, or a pharmaceutically acceptable
10 salt thereof, for the manufacture of a medicament for treating cancer.

15